A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors

被引：0
|
作者：
Hansen, M
Gimsing, P
Rasmussen, A
Jensen, PB
Knudsen, LM
机构：
[1] Rigshosp, DK-2100 Copenhagen, Denmark
[2] Topotarget AS, Copenhagen, Denmark
[3] Herlev Univ Hosp, Copenhagen, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225S / 225S
页数：1
相关论文
共 50 条
  • [31] Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms
    Odenike, O.
    Green, M.
    Larson, R. A.
    Rich, E. S.
    Ott, J.
    Ratain, M. J.
    Stock, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [33] NANOPARTICLE DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR PXD101 FACILITATES BLADDER CANCER CELL UPTAKE AND CYTOTOXICITY
    Kaimakliotis, Hristos Z.
    Martin, Darryl T.
    Hoimes, Christopher J.
    Cheng, Christopher C.
    Liu, Jingchun
    Kelly, Wm. Kevin
    Tew, Gregory N.
    Saltzman, W. Mark
    Weiss, Robert M.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E542 - E542
  • [34] The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Joanne Yoon
    Herman Yee
    Luis Chiriboga
    Leonard Liebes
    Gulshan Ara
    Xiaozhong Qian
    Dean F Bajorin
    Tung-Tien Sun
    Xue-Ru Wu
    Iman Osman
    Journal of Translational Medicine, 5
  • [35] A phase II study of PXD101 in advanced multiple myeloma.
    Sullivan, Daniel
    Singhal, Seema
    Schuster, Michael
    Berenson, James
    Gimsing, Peter
    Wisloff, Finn
    Waage, Anders
    Alsina, Melissa
    Gerwien, Robert
    Clarke, Anne
    Moller, Karen
    Ooi, Chean Eng
    BLOOD, 2006, 108 (11) : 1023A - 1023A
  • [36] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [37] A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocelluar carcinoma
    Yeo, W.
    Lim, R.
    Ma, B. B.
    Hui, P.
    Chan, L.
    Mo, F. K.
    Yu, S. C.
    Ho, S. S.
    Koh, J.
    Chan, A. T.
    Goh, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
    Zain, J. M.
    Foss, F.
    Kelly, W. K.
    DeBono, J.
    Petrylak, D.
    Narwal, A.
    Neylon, E.
    Blumenschein, G.
    Lassen, U.
    O'Connor, O. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Defining a set of genes dysregulated in response to the HDAC inhibitor PXD101 (belinostat)
    Shoemaker, Robert H.
    Hose, Curtis D.
    Pezzoli, Patrick
    Vansant, Gordon
    Sehested, Maxwell
    Monforte, Joseph
    Monks, Anne
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3377S - 3377S
  • [40] The histone deacetylase inhibitor PXD101 inhibits the growth of human ovarian and colon tumour xenografts in vivo.
    Plumb, JA
    Williams, RJ
    Finn, PW
    Bandara, MJ
    Romero, MR
    Watkins, CJ
    La Thangue, NB
    Brown, R
    BRITISH JOURNAL OF CANCER, 2002, 86 : S16 - S16
12345